oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium.
Örebro University, School of Health Sciences.
Statens Serum Institut, Copenhagen, Denmark.
2017 (English)In: Nature reviews. Urology, ISSN 1759-4812, E-ISSN 1759-4820, Vol. 14, no 3, 139-152 p.Article in journal (Refereed) Published
Abstract [en]

The emergence of antimicrobial resistance (AMR) is a major concern worldwide and already compromises treatment effectiveness and control of several bacterial sexually transmitted infections (STIs). Neisseria gonorrhoeae and Mycoplasma genitalium are evolving into so-called superbugs that can become resistant, both in vitro and clinically, to essentially all antimicrobials available for treatment, causing exceedingly difficult-to-treat or untreatable STIs and threatening global public health. Widespread AMR in these bacteria is likely to persist and even worsen in the future, owing to the high number of infections, widespread and uncontrolled use of antimicrobials, limited surveillance of AMR and clinical failures, as well as the extraordinary capacity of these bacteria to develop AMR. This development would not only result in an increased prevalence of N. gonorrhoeae and M. genitalium infections but also in a considerably increasing number of severe complications affecting reproductive health. To combat this threat, clinicians need to be aware of the current guidelines on diagnostic procedures, recommended treatment regimens, as well as therapeutic options for multidrug-resistant bacteria. AMR testing needs to be more frequently performed, inform treatment decisions and elucidate how AMRs compromise treatment effectiveness, guiding research for effective future therapies.

Place, publisher, year, edition, pages
Nature Publishing Group, 2017. Vol. 14, no 3, 139-152 p.
National Category
Urology and Nephrology
Research subject
Infectious Diseases
Identifiers
URN: urn:nbn:se:oru:diva-57407DOI: 10.1038/nrurol.2016.268ISI: 000395796800010PubMedID: 28072403ScopusID: 2-s2.0-85009212751OAI: oai:DiVA.org:oru-57407DiVA: diva2:1092313
Note

Funding Agenciees:

Orebro University Hospital Foundation, Orebro, Sweden

Available from: 2017-05-02 Created: 2017-05-02 Last updated: 2017-05-02Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Unemo, Magnus
By organisation
School of Health Sciences
In the same journal
Nature reviews. Urology
Urology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 3 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf